AstraZeneca Bets $2 Billion on Summit
AstraZeneca has agreed to invest $2 billion in Summit Therapeutics, giving the biotech a major capital infusion as it advances its cancer-drug pipeline. Summit shares jumped more than 15% in after-hours trading following the announcement. (Sources: Reuters, Barron's, MarketScreener)
Summit Shares Surge
Summit’s stock rose sharply after the deal was announced, with shares trading as much as 19% above Monday’s close in extended trading. The company had closed at $15.48 before the announcement.
AstraZeneca to Take Stake
Once converted, AstraZeneca will have rights equivalent to roughly 12% of Summit’s outstanding common stock, or about 10.6% on a fully diluted basis. The preferred-share transaction is expected to close within a week, subject to customary conditions.
Ivonescimab at the Centre
The investment is closely tied to ivonescimab, Summit’s lead experimental cancer treatment. The PD-1/VEGF bispecific antibody was developed by China’s Akeso, while Summit holds development and commercialisation rights across major markets outside China.
New Cancer-Drug Combination
Summit and AstraZeneca also plan clinical trials combining ivonescimab with sonesitatug vedotin, AstraZeneca’s Claudin 18.2-targeting antibody-drug conjugate. Initial studies are planned in gastrointestinal cancers.
A Cash Boost for Development
The $2 billion investment gives Summit additional financial resources as it funds late-stage clinical development of ivonescimab. The companies will contribute their respective medicines and share costs for planned combination trials, while retaining commercial rights to their own drugs.
FDA Decision Ahead
Investors are also watching the regulatory path for ivonescimab. The U.S. FDA is reviewing Summit’s application for the drug in combination with chemotherapy for EGFR-mutated non-small-cell lung cancer, with a decision expected by November 14, 2026.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Read more onAstraZenecaSummit Therapeutics$2 Billion InvestmentIvonescimabCancer DrugsFDAGastrointestinal CancerPharmaceutical IndustryStock MarketEnter search text:BrowseCompanies:ABCDEFGHIJKLMNOPQRSTUVWXYZ123456789
